Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
Abraxis BioScience, Inc. (ABII) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/06/2010 8-K Quarterly results
Docs: "ABRAXIS BIOSCIENCE REPORTS FIRST QUARTER 2010 FINANCIAL RESULTS • ABRAXANE ® First Quarter 2010 Revenue Grows 25% to $88 Million Compared to the First Quarter of 2009 • Company Reports First Quarter 2010 Net Loss for Common Shareholders of $3 Million, or $0.07 Per Share, with Adjusted Net Income of $9 Million, or $0.22 Per Share"
03/11/2010 8-K Form 8-K - Current report
11/05/2009 8-K Quarterly results
Docs: "ABRAXIS BIOSCIENCE REPORTS 2009 THIRD QUARTER FINANCIAL RESULTS Third Quarter Highlights:"
08/06/2009 8-K Quarterly results
Docs: "ABRAXIS BIOSCIENCE REPORTS 2009 SECOND QUARTER FINANCIAL RESULTS Second Quarter Highlights: • ABRAXANE ® Revenue Grows to $75 Million, Representing a 6 Percent Sequential Quarterly Increase • Company Reports Net Loss for Common Shareholders of $23 Million, or $0.58 Per Share, or Adjusted Net Loss for Common Shareholders of $10 Million, or $0.25 Per Share"
05/07/2009 8-K Form 8-K -- Current report
03/03/2009 8-K Form 8-K -- Current report
05/15/2008 8-K Quarterly results
Docs: "ABRAXIS BIOSCIENCE REPORTS 14% REVENUE GROWTH TO $82.1 MILLION FOR THE FIRST QUARTER OF 2008 Highlights"
04/01/2008 8-K Quarterly results
Docs: "ABRAXIS BIOSCIENCE REPORTS 83% REVENUE GROWTH TO A RECORD $334 MILLION FOR 2007 Highlights • ABRAXANE Revenue for Q4 2007 Increased 58% to $88.8 Million Versus $56.1 Million in Q4 2006 • ABRAXANE Continues to be Fastest Growing Taxane and Achieves All Time High of 37% Market Share in Feb 2008 • Company to Initiate Five Phase III Trials for ABRAXANE in 2008"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy